Somatostatin release by glutamate in vivo is primarily regulated by AMPA receptors

We have used in vivo microdialysis in anaesthetized rats to investigate whether levels of striatal somatostatin (SRIF) can be increased in response to application of the ionotropic glutamate receptor agonists AMPA and NMDA. Application of both AMPA and NMDA (10, 50, 100 and 500 μ M ) for 20 min periods produced concentration‐dependent increases in the extracellular levels of SRIF. A 500 μ M dose of each compound was shown to be the most potent concentration tested, increasing levels of SRIF by 32 fold (NMDA) and 35 fold (AMPA). At lower concentrations (10 μ M ) NMDA failed to evoke significant amounts of SRIF while AMPA increased levels of the peptide 2.3 fold. Application of the respective receptor antagonists APV (NMDA receptor) and DNQX (AMPA receptor) abolished the abilities of the agonists to evoke release of SRIF. Interestingly DNQX abolished the ability of NMDA to evoke release of the peptide as well. The ability of both AMPA and NMDA to evoke increases in the levels of extracellular SRIF further illustrates the reciprocal relationship that exists between SRIF and glutamate in the striatum which impacts particularly on dopaminergic functioning in this region.British Journal of Pharmacology (2001) 134 , 1155–1158; doi: 10.1038/sj.bjp.0704362